 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Santarus (SNTS) is a specialty biopharmaceutical company.
It engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists.
The company offers Uceris extended release tablets for the induction of remission in active, mild to moderate ulcerative colitis; Zegerid to treat certain upper gastrointestinal conditions; and Fenoglide fenofibrate tablets marketed as an adjunct to diet to treat high cholesterol.
It also provides Glumetza metformin hydrochloride extended release tablets and Cycloset bromocriptine mesylate tablets marketed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. In addition, the company focuses on advancing investigational drugs to commercialization, including Ruconest, a recombinant human C1 esterase inhibitor that has completed Phase III clinical study for treatment of acute attacks of angioedema in patients with hereditary angioedema; Rifamycin SV MMX, which has completed Phase III clinical study for treatment of travelers diarrhea; and SAN-300, an anti-VLA-1 antibody that has completed a Phase I dose-escalation clinical study for the treatment of rheumatoid arthritis.
Santarus and Pharming Group NV, its partner, today announced the submission of a Biologics License Application to the FDA to obtain marketing approval for RUCONEST 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Shares have formed a bullish "cup & handle" and higher prices are expected for this stock.
52-Week Trading Range: $4.82 - $18.77
Entry Point: $18.20
Stop Loss: $17.30
Target Price: $20.10
Our target on SNTS was $20.10. Stock gapped up this morning and we closed the position at $21.75.
